Your session is about to expire
← Back to Search
Combination Chemotherapy + Immunotherapy for Acute Lymphoblastic Leukemia
Study Summary
This trial is studying a combination of immunotherapy and chemotherapy drugs to see if they are more effective than standard treatments for acute lymphoblastic leukemia.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have a serious infection that isn't getting better with antibiotics.I am 18 or older with untreated Ph-positive ALL or advanced CML.I am 18 or older with specific types of leukemia that have not responded to treatment.I am 18 or older with specific types of leukemia.I can take care of myself but might not be able to do heavy physical work.My liver is working well.My heart is functioning well, as assessed by a doctor.I have had a significant blood clot in my veins or arteries.I am of childbearing age and have a negative pregnancy test.I am a woman who is either postmenopausal, surgically sterile, or agrees to use contraception.I am a male and will use effective contraception or practice abstinence.I have had pancreatitis within the last year or suffer from chronic pancreatitis.I do not have any active heart conditions.I haven't taken any experimental cancer drugs or chemotherapy in the last 2 weeks.I do not have an active HIV, HBV, or HCV infection.I have or had an autoimmune disease that could affect my brain or nerves.My high blood pressure is not under control.I have significant fluid buildup in my chest or around my heart.I have another cancer besides skin cancer.My pancreas works well.I have severe heart failure.I have been diagnosed with a specific condition.I have a significant brain condition or event in my medical history.I have a history of serious bleeding problems not related to my cancer.I have very high triglyceride levels that aren't managed.
- Group 1: Treatment (blinatumomab, chemotherapy, ponatinib)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the scale of enrollment for this trial?
"Affirmative, information posted on clinicaltrials.gov confirms that this research endeavor is actively enlisting volunteers. This study was initially advertised in November 2017 and its most recent update occurred during the month of June 2022. The trial requires 90 participants to be sourced from a single medical centre."
Are there any openings in this clinical experiment that require participation?
"As indicated on clinicaltrials.gov, this research is presently recruiting participants and was originally uploaded on November 29th 2017 with the most recent alteration being made on June 21st 2022."
To what degree can Ponatinib be considered hazardous to those partaking in the treatment?
"Ponatinib's safety has been supported by preliminary data, so it was given a rating of 2. Unfortunately, there is currently no clinical research supporting its efficacy for this purpose."
In what medical scenarios is Ponatinib often prescribed?
"Ponatinib is primarily used for liver transplantation, yet it can also provide relief from meningeal leukemia, small cell lung cancer (SCLC), and active pauciarticular juvenile rheumatoid arthritis."
Share this study with friends
Copy Link
Messenger